Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Tangible Net Worth Ratio
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Tangible Net Worth Ratio of 96.9% as of March 2026. This metric is calculated by deducting intangible assets (CN¥69.93 Million) from net assets (CN¥2.28 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See how liquid is Hubei Biocause Heilen Pharmaceutical Co.'s working capital to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Tangible Net Worth Ratio (2017–2025)
This chart shows how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s Tangible Net Worth Ratio has changed across 9 annual periods from 2017 to 2025. As of March 2026, the ratio stands at 96.9%, reflecting net assets of CN¥2.28 Billion with intangible assets of CN¥69.93 Million CNY. See defensive interval ratio of Hubei Biocause Heilen Pharmaceutical Co. to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025, covering 9 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Hubei Biocause Heilen Pharmaceutical Co. (301211) total market value.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 96.9% | CN¥2.27 Billion | CN¥70.44 Million | CN¥2.40 Billion | ▼ -0.1 pp |
| 2024 | 97.0% | CN¥2.31 Billion | CN¥68.94 Million | CN¥2.49 Billion | ▲ +0.0 pp |
| 2023 | 97.0% | CN¥2.36 Billion | CN¥71.07 Million | CN¥2.55 Billion | ▲ +0.2 pp |
| 2022 | 96.8% | CN¥2.28 Billion | CN¥73.27 Million | CN¥2.50 Billion | ▼ -0.2 pp |
| 2021 | 97.0% | CN¥2.22 Billion | CN¥66.67 Million | CN¥2.33 Billion | ▲ +5.8 pp |
| 2020 | 91.2% | CN¥700.39 Million | CN¥61.45 Million | CN¥803.25 Million | ▼ -0.6 pp |
| 2019 | 91.8% | CN¥488.25 Million | CN¥40.06 Million | CN¥745.56 Million | ▼ -0.2 pp |
| 2018 | 92.0% | CN¥399.87 Million | CN¥31.99 Million | CN¥640.24 Million | ▲ +6.0 pp |
| 2017 | 86.0% | CN¥307.65 Million | CN¥43.07 Million | CN¥534.90 Million | — |